Industry news: Lilly's salary cap; Hatch takes hatchet to medical device tax

Share this article:
The flow of generic versions of Lilly's anti-psychotic drug Zyprexa and chemotherapy drug Gemzar is taking a bite out of sales and salaries, so much so that the company is freezing salaries for most of its employees, Bloomberg reported on Friday. The company's CEO and President, John C. Lechleiter Ph.D, is among those who will not be seeing a salary bump in 2012 and will retain his $1.5 million base salary. His overall compensation is valued at approximately $16.4 million, reports RTT news. The company saw overalls sales drop 2% in the fourth quarter.The biggest falloff was for the anti-psychotic Zyprexa, which saw sales plummet 44% for the quarter and 8% for the year.

Utah Sen. Orrin Hatch assailed a tax on medical devices such as artificial hips and knees as a job killer.The IRS announced the 2.3% tax Friday. It is expected to go into effect next year and raise $28.5 billion over the course of 10  years. Hatch said the tactic “is exactly the wrong thing under a weak economy. This is a tax on innovation and job creation that will ultimately stifle the development of life-saving medical devices with costs that will be passed on to consumers.” The tax is part of the Affordable Health Care Act. Hatch sponsored a bill January 25 to repeal the tax.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.